Vaccinia Viral Vector Service

Vaccinia virus (VACV or VV) is a large, complex enveloped virus belonging to the poxvirus family. It has a linear double-stranded DNA genome of approximately 190 kb, which can encode approximately 250 genes. The genome is surrounded by a lipoprotein core membrane. Poxviruses are the largest known DNA viruses. The difference from other viruses is that they can replicate completely in the cytoplasm of the host cell (outside the nucleus). Vaccinia virus is known for its role as a vaccine to eradicate smallpox disease, making it the first human disease successfully eradicated by humans. This work is carried out by the World Health Organization (WHO) Smallpox Eradication Program. After the eradication of smallpox, scientists studied the vaccinia virus and used it as a tool to deliver genes into biological tissues (gene therapy and genetic engineering).

Construction of vaccinia virus vector

  • Construction of vaccinia virus vector
  • Vaccinia virus can generally accommodate foreign DNA exceeding 30 kb. Exogenous genes can be stably integrated into the viral genome to achieve effective and long-term gene expression. The redesigned attenuated vaccinia virus produced by different strains has proven to be non-toxic and safe to humans. The deletion of the viral genes of thymidine kinase (TK) and vaccinia growth factor (VGF) leads to enhanced tumor targeting activity and completely retains their replication efficiency in cancer cells. The vaccinia virus vector has been engineered to express various immune antigens and used for cancer treatment, including breast cancer, colorectal cancer, glioblastoma, lung cancer, pancreatic cancer and prostate cancer.

  • Vaccinia virus vector development
  • The development of vectors based on attenuated vaccinia virus has resolved concerns about the safety of vaccinia virus. Recombinant vaccinia viruses have been produced from different vaccinia virus strains. Some highly attenuated, host-restricted, non-replicating or poorly replicating poxvirus strains have been developed to be used as substrates in the development of recombinant vaccines. These strains include orthopox virus, modified vaccinia Ankara (MVA) and NYVAC (derived from Copenhagen vaccinia strain), and fowlpox virus, ALVAC and TROVAC (derived from canarypox virus and fowlpox virus, respectively).

Our advantages

  • High insertion ability for a variety of foreign genes
  • Low cytotoxicity (ultracentrifugation purification process)
  • No mycoplasma contamination
  • No endotoxin, exogenous microorganisms, no acid host nucleus residue
  • Strong customer-centric after-sales service system

Our service items

Project name Vaccinia viral vector service
Our services
  • Construction of vaccinia virus vector
  • Vaccinia virus vector development
Product delivery mode We will complete the project on time according to the agreed time, summarize the experimental data and conclusions, and complete the experimental report.
Price Inquiry

Why choose us?

CD BioSciences provides professional vaccinia viral vector service, which can meet the needs of regular customers for hit identification on time and on budget. CD BioSciences relies on world-class viral vector technology expertise, we provide the highest quality one-stop vaccinia viral vector service for gene delivery, including the design and construction of vaccinia vectors according to different experimental needs. Please feel free to contact us for more detailed information, our scientists will tailor the most reasonable plan for your project.


Copyright © CD BioSciences. All rights reserved.